[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Metagenics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":82},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100631975","impact-of-metacalm-on-stress-of-healthy-people-with-acute-stress-100631975",false,"NCT07507669","Impact of MetaCalm on Stress of Healthy People With Acute Stress","Evaluation of MetaCalm at Two Dose Levels in Healthy Adults With Acute Stress: An Open-Label, Non-Randomized Clinical Study","Inclusion Criteria:\n\n* Providing written informed consent\n* Males and females of at least 18 years old\n* Obtaining a reference score of ≥ 30 on the STAI questionnaire (State-Trait Anxiety Inventory, short version, 10-item scale)\n\nExclusion Criteria:\n\n* Being on anxiolytic and beta blocker treatment\n* Individuals who use illicit or recreational drugs\n* Having consumed adaptogen plants in one week prior to enrollment\n* Participating in another clinical trial\n* Patients diagnosed with cancer\n* Allergic to any of the ingredients in this product\n* Obtaining a reference score of less than 30 on the STAI questionnaire (State-Trait Anxiety Inventory, short version, 10-item scale)",true,"ALL","18 Years",{"count":20,"type":21},280,"ESTIMATED","INTERVENTIONAL",[24],"NA","This Open-Label, Non-Randomized Clinical Study involving 280 participants who will undergo a total participation of 6 hours.",[27,28],"Adults","Acute Stress Reaction","NOT_YET_RECRUITING","2026-04-08",{"date":32,"type":33},"2026-04-13","ACTUAL",{"date":35,"type":21},"2026-04-15",{"date":37,"type":21},"2026-08-31",{"name":39,"class":40},"Metagenics, Inc.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100609014","impact-of-probiotic-ultraflora-triplebiotic-on-weight-evolution-on-people-after-discontinuation-of-glp-1-treatment-100609014","NCT07209046","Impact of Probiotic (UltraFlora® Triplebiotic) on Weight Evolution on People After Discontinuation of GLP-1 Treatment.","A Randomized, Double-blind, Double-arm Study Conducted Directly With Consumers Via an App \"Baritastic App\", Evaluating the Efficacy of a Supplement Containing Bifidobacterium Lactis B420 and Pasteurized Akkermansia Muciniphila (UltraFlora® Triplebiotic) for 3 Months in Adults After Discontinuation of GLP-1 Treatment.","Inclusion Criteria:\n\n1. Providing written informed consent\n2. Males and females of at least 18 years old\n3. Body mass index (BMI) between 25 and 30 (including 25 and 30) (Weight: 25 \\\u003C BMI \\\u003C 30)\n4. Having undergone treatment with GLP-1 for more than 3 months but for less than 1 year.\n5. Having stopped GLP-1 treatment for a maximum of 4 weeks\n6. Being willing to maintain stable dietary habits and physical activity levels throughout the trial period\n7. Being willing not to introduce any other food supplements during the trial period (supplements used in the two weeks prior to enrolling in the trial and used consistently throughout are acceptable, except for probiotics).\n\nExclusion Criteria:\n\n1. Being on GLP-1 treatment\n2. Having had any type of bariatric surgery, or planned bariatric surgery during the period of trial participation.\n3. Suffering from a severe chronic disease (e.g., cancer, HIV, hepatic or renal impairment, diabetes type I), inflammatory bowel disease (IBD), Coeliac Disease, and\u002For being immunocompromised.\n4. Suffering from any uncontrolled endocrine disorder.\n5. Having consumed any probiotic supplements in the 3 months prior to enrollment.\n6. Having used any antibiotic treatment in the 3 months prior to enrollment.\n7. Having a known allergy to the ingredients in the study product.\n8. Being pregnant or lactating (breastfeeding) or trying to become pregnant.\n9. Participating in an other clinical trial.\n10. Suffering from dementia or inability to take the trial treatment in an appropriate way.\n11. Taking UltraFlora® Triplebiotic or any similar product from competitors prior to trial participation",{"count":50,"type":21},128,[24],"This is a randomized, double-blind, double arm study involving 128 participants who will undergo a total participation period of 12 weeks.",[27,54],"GLP-1","2025-09-29",{"date":57,"type":33},"2025-10-06",{"date":59,"type":21},"2025-11-01",{"date":61,"type":21},"2026-07-31",{"name":39,"class":40},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100602967","impact-of-multivitamin-phytomulti-and-a-probiotic-ultraflora-balance-probiotic-on-gut-health-of-people-taking-glp-1-medication-100602967","NCT07130396","Impact of Multivitamin (PhytoMulti®) and a Probiotic (UltraFlora® Balance Probiotic) on Gut Health of People Taking GLP-1 Medication","A Single Arm Trial to Evaluate the Effect of PhytoMulti® Multivitamin and UltraFlora® Balance Probiotic on Bowel Symptoms in Individuals Using GLP-1 Receptor Agonists, Assessed by the IBS Symptom Severity Score (IBS-SSS)","Inclusion Criteria:\n\n1. Providing written informed consent\n2. Males and females of at least 18 years old\n3. Minimum 4 weeks on GLP-1 (f.e Ozempic®, Wegovy®, Mounjaro®, etc.) and maximum 1 year on GLP-1\n4. Body Mass Index (BMI) ≥ 25 AND ≤ 30\n5. Being willing to maintain stable dietary habits and physical activity levels throughout the trial period\n6. Being willing not to introduce any other food supplements during the trial period (supplements used in the two weeks prior to enrolling in the trial and used consistently throughout are acceptable, except for probiotics).\n\nExclusion Criteria:\n\n1. Having had any type of bariatric surgery, or planned bariatric surgery during the period of trial participation.\n2. Suffering from a severe chronic disease (e.g., cancer, HIV, hepatic or renal impairment, diabetes type I), inflammatory bowel disease (IBD), Coeliac Disease, and\u002For being immunocompromised.\n3. Suffering from any uncontrolled endocrine disorder\n4. Having used any antibiotic treatment in the 2 months prior to enrollment.\n5. Having a known allergy to the ingredients in the study product.\n6. Being pregnant or lactating (breastfeeding) or trying to become pregnant.\n7. Participating in another clinical trial.\n8. Suffering from dementia or inability to take the trial treatment in an appropriate way.\n9. Taking PhytoMulti® Multivitamin and\u002For UltraFlora® Probiotic or any similar product from competitors prior to trial participation",{"count":71,"type":21},100,[24],"This is a single-arm, open-label clinical trial involving 100 participants who will undergo a total participation period of 12 weeks.",[54,27],"2025-08-12",{"date":77,"type":33},"2025-08-19",{"date":59,"type":21},{"date":80,"type":21},"2026-04-30",{"name":39,"class":40},""]